Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

NCT03233191 · View on ClinicalTrials.gov ↗

Study Summary

This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

Conditions Studied

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Digital Tomosynthesis Mammography
  • PROCEDURE Digital Mammography

Study Locations (20)

Colorado

  • UCHealth University of Colorado Hospital — Aurora
  • Penrose-Saint Francis Healthcare — Colorado Springs
  • The Women's Imaging Center — Denver
  • Radiology Imaging Associates — Englewood
  • UCHealth Highlands Ranch Hospital — Highlands Ranch
  • UCHealth Lone Tree Health Center — Lone Tree

Arizona

  • Banner-University Medical Center Phoenix — Phoenix
  • University of Arizona College of Medicine Phoenix — Phoenix
  • Valleywise Comprehensive Health Center - Phoenix — Phoenix
  • Mayo Clinic Hospital in Arizona — Phoenix
  • Scottsdale Medical Imaging Limited — Scottsdale

California

  • Kern Radiology Medical Group Inc — Bakersfield
  • Los Angeles General Medical Center — Los Angeles
  • USC / Norris Comprehensive Cancer Center — Los Angeles
  • Kaiser Permanente-Modesto — Modesto
  • Zuckerberg San Francisco General Hospital — San Francisco

Alabama

  • University of Alabama at Birmingham Cancer Center — Birmingham
  • Mobile Infirmary Medical Center — Mobile

Arkansas

  • University of Arkansas for Medical Sciences — Little Rock

Delaware

  • Helen F Graham Cancer Center — Newark

Trial Details

FieldValue
Enrollment Target 108,508 participants
Start Date 2017-09-28
Est. Completion 2030-12-31
Phase Phase 3

Sponsor

ECOG-ACRIN Cancer Research Group

52 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03233191

The ClinicalTrials.gov registry entry for NCT03233191 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 108,508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Breast Screening appearing as the primary indexed condition, and to 3 interventions — of which Laboratory Biomarker Analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03233191 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Colorado, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03233191 about?

NCT03233191 is a clinical study titled "Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer". This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for ad...

What is the current status of trial NCT03233191?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 108,508 participants. The study started on 2017-09-28. Estimated completion is 2030-12-31.

What conditions does trial NCT03233191 study?

This clinical trial studies the following conditions: Breast Screening. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03233191?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Digital Tomosynthesis Mammography (PROCEDURE), Digital Mammography (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03233191?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03233191 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial